HYPERCALCEMIA OF MALIGNANCY AND UPDATE MANAGEMENT
Keywords:
Hypercalcemia, malignancy, parathyroid hormone, bisphosphonate, denosumabAbstract
Hypercalcemia is the most common medical complication of malignancies We aimed to provide updated research on the incidence, pathogenesis, clinical manifestation, diagnostic approach, and management of hypercalcemia of malignancy. Review and summarize the published literature to date from PubMed, Ovid, and medRxiv Data sources from 1973 to April 2022
Major mechanisms of hypercalcemia of malignancy included tumor secreting parathyroid related proteins, osteolytic metastases, and tumor production of 1,25-dihydroxy vitamin D. In the cancer patient with hypercalcemia, adequate intravenous hydration, using the medication that increases renal calcium excretion and anti-reabsorptive drugs were necessary along with the primary cancer treatment.
Malignancy-related hypercalcemia associated with high hospitalization and mortality rate in patients. Appropriate treatment may have minimized symptoms, improved the quality of life, and increased cancer management chances.
Downloads
References
Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373.
Gardner DG. Endocrine emergencies. In Greenspan’s Basic and Clinical Endocrinology, 8th ed., chapter 25, pp. 882–884. Eds DG Gardner & D Shoback. New York: McGraw Hill, 2018.
Ralston SH, Gallacher SJ, Patel U, Campbell J & Boyle IT. Cancerassociated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Annals of Internal Medicine. 1990; 112 499–504.
Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer. 2005; 12:549.
Mirrakhimov AE. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci. 2015; 7:483.
Guise TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. N Engl J Med. 2022; 386:1443.
Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet. 1992; 339:164.
Ikeda K, Ohno H, Hane M. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab. 1994; 79:1322.
Powell D, Singer FR, Murray TM, Minkin C & Potts JT Jr. Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases. N Engl J Med. 1973; 289: 176–181.
Mundy GR & Martin TJ. The hypercalcemia of malignancy: pathogenesis and management. Metabolism: Clinical and Experimental. 1982. 31; 1247–77.
Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet. 1993; 341:1611.
Ling PJ, A'Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hypercalcemia with intravenous pamidronate (APD). Br J Cancer. 1995; 72:206.
Horwitz MJ. Non-parathyroid hypercalcemia. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed, Bilezikian JP (Ed), Wiley-Blackwell, Hoboken, NJ 2018. p.639.
Edwards CM, Silberman R. Myeloma bone disease and other hematological malignancies. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed, Bilezikian JP (Ed), Wiley-Blackwell, Hoboken, NJ 2018. p.760.
Grill V, Ho P, Body JJ, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab. 1991; 73:1309.
Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood. 1993; 82:1383.
Hibi M, Hara F, Tomishige H. 1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol. 2008; 25:73.
Scheinman SJ, Kelberman MW, Tatum AH, Zamkoff KW. Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma. Am J Med Sci. 1991; 301:178.
El-Hajj Fuleihan G, Clines GA, Hu MI. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023; 108:507.
Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med. 1981; 50:473.
Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015; 350:h2723.
Singer FR, Ritch PS, Lad TE. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med. 1991; 151:471.
Gucalp R, Theriault R, Gill I. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med. 1994; 154:1935.
Major P, Lortholary A, Hon J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19:558.
Seisa MO, Nayfeh T, Hasan B, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults. J Clin Endocrinol Metab. 2023; 108:585.
Jansson S, Tisell LE, Lindstedt G, Lundberg PA. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery. 1991; 110:480.
Horwitz MJ. Non-parathyroid hypercalcemia. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed, Bilezikian JP (Ed), Wiley-Blackwell, Hoboken, NJ 2018. p.639.
Major P, Lortholary A, Hon J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19:558.
Dietzek A, Connelly K, Cotugno M. Denosumab in hypercalcemia of malignancy: a case series. J Oncol Pharm Pract. 2015; 21:143.
Bech A, de Boer H. Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med. 2012; 156:906.
Hu MI, Glezerman IG, Leboulleux S. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014; 99:3144.
Stopeck AT, Lipton A, Body JJ. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer. J Clin Oncol. 2010; 28:5132-9.
Henry DH, Costa L, Goldwasser F. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29:1125-32.
Diel IJ, Body JJ, Stopeck AT. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer. 2015; 51:1467-75.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Kalasin Provincial Public Health Office
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารศูนย์ดัชนีการอ้างอิงวารสารไทย ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใด ๆบทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารศูนย์ดัชนีการอ้างอิงวารสารไทย ถือเป็นลิขสิทธิ์ของวารสารศูนย์ดัชนีการอ้างอิงวารสารไทย หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใด จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษรจากวารสารศูนย์ดัชนีการอ้างอิงวารสารไทยก่อนเท่านั้น
